'Make America Healthy Again' platform to be a top priority of RFK Jr. at HHS
With Robert F. Kennedy Jr. set to be sworn in as HHS secretary later Thursday, one of the first tasks in his new position ...
Palatin Technologies, Inc.: Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...
ophthalmologyadvisor2d
Weight-Loss Drugs May Elevate NAION Risk, Although Causal Link Remains Unproven
Weight-loss drugs such as semaglutides or tirzepatides may raise patients’ risk of nonarteritic anterior ischemic optic ...
T-Net2d
Lexaria Updates its Ongoing Human Study GLP-1-H24-4
Lexaria Bioscience Corp., a global innovator in drug delivery platforms, provided progress updates on its Phase 1b, 12-week ...
Eli Lilly pledges $630m on OliX’s Phase I RNA candidate for MASH
Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.
The Pharma Letter3d
OliX and Lilly ink licensing deal
South Korea-based developer of RNAi therapeutics developer OliX Pharmaceuticals has announced a global licensing agreement with Eli Lilly.
Smaller biotechs see new mechanisms of actions as future of obesity treatments
Several small biotechs working on new treatments for weight loss believe that developing therapies with mechanism of actions not seen with current drugs, such as those from Novo Nordisk (NVO) and Eli ...
FierceBiotech4d
Eli Lilly inks duo of deals, teaming with AdvanCell, OliX to push deeper into radiopharma, MASH
Eli Lilly has begun the week with a bang. Early Monday morning, AdvanCell and OliX Pharmaceuticals put out news that the Big ...